Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Interventions for hidradenitis suppurativa

Ingram, John R. 2017. Interventions for hidradenitis suppurativa. JAMA Dermatology 153 (5) , pp. 458-459. 10.1001/jamadermatol.2017.0432

Full text not available from this repository.

Abstract

Clinical Question: Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults? Bottom Line: There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, −3.7 to −2.0 points) and 1.6 points (95% CI, −3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: American Medical Association
ISSN: 2168-6068
Last Modified: 15 Jul 2019 10:10
URI: http://orca.cf.ac.uk/id/eprint/100492

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item